NEW YORK--(BUSINESS WIRE)--Omrix Biopharmaceuticals, Inc. ("Omrix" or the "Company") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, today provided preliminary unaudited product sales for the third quarter ended September 30, 2008 and increased its 2008 product sales guidance.
